Frank Osterkamp

USPTO Granted Patents = 23 (Patent Applications = 8)

CIPO Patents = 7 (Patent Applications = 6)

EPO Patents = 9 (Patent Applications = 19)

Average Co-Inventor Count = 8.0

ph-index = 4

Forward Citations = 68(Granted Patents)

Company Filing History:

Shire Orphan Therapies Gmbh

patents

3 out of 2,480

Baxter International Inc.

3b Pharmaceuticals Gmbh

Shire Orphan Thereapies Gmbh

patent

8. 1 out of 3

Jpt Peptide Technologies Gmbh

patents

9. 1 out of 1,177

Takeda Pharmaceutical Company Limited

patents

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

23 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12427210 - Compounds comprising a fibroblast activation protein ligand and use thereof (2025-09-30),

2. 11793855 - TFPI inhibitors and methods of use (2023-10-24),

3. 10961199 - Neurotensin receptor ligands (2021-03-30),

4. 10800816 - TFPI inhibitors and methods of use (2020-10-13),

5. 10799605 - Conjugate comprising a neurotensin receptor ligand and use thereof (2020-10-13),

6. 10201586 - TFPI inhibitors and methods of use (2019-02-12),

7. 10196423 - NPR-B agonists (2019-02-05),

8. 10124033 - Peptides and methods of use (2018-11-13),

9. 9982016 - NPR-B agonists (2018-05-29),

10. 9873720 - TFPI inhibitors and methods of use (2018-01-23),

11. 9745344 - NPR-B agonists (2017-08-29),

12. 9556230 - TFPI inhibitors and methods of use (2017-01-31),

13. 9458198 - Cyclic peptide-based NPR-B agonists (2016-10-04),

14. 9447147 - Peptides and methods of use (2016-09-20),

15. 9169293 - NPR-B agonists (2015-10-27),

Title: Frank Osterkamp: Innovator in Therapeutic Peptides

Introduction: Frank Osterkamp is a prominent inventor based in Berlin, Germany, known for his significant contributions to the field of medicinal chemistry. With an impressive portfolio of 22 patents, Osterkamp has focused on developing innovative therapeutic solutions that address critical health issues.

Latest Patents: Among Osterkamp's latest patents are pioneering inventions related to Tissue Factor Pathway Inhibitors (TFPI) and neurotensin receptor ligands. The first invention provides peptides that bind TFPI, offering potential applications in inhibiting TFPI, enhancing thrombin formation in individuals with clotting factor deficiencies, improving blood clot formation, treating blood coagulation disorders, purifying TFPI, and identifying TFPI-binding compounds. The second patent involves a compound formula aimed at optimizing neurotensin receptor activity, which may lead to new insights in neuropharmacology.

Career Highlights: Frank Osterkamp has worked with esteemed companies in the biotechnology industry, including Baxalta GmbH and Shire Orphan Therapies GmbH. His career is marked by a focus on innovation and a commitment to improving therapeutic outcomes through cutting-edge research and development.

Collaborations: Throughout his career, Osterkamp has collaborated with notable colleagues, including Ulrich Reineke and Michael Dockal. Together, they have advanced the understanding of peptide therapeutics and contributed to the development of novel treatments.

Conclusion: Frank Osterkamp stands out as a leading inventor in the realm of therapeutic innovations. His work in peptide development and his extensive patent portfolio showcase his dedication to advancing medical science and improving patient care. As the landscape of medicinal chemistry continues to evolve, Osterkamp's contributions will undoubtedly play a vital role in shaping the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.